Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.

An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.68% at $440.87. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow gained 0.08% ...

Vertex Pharmaceuticals Inc. closed 15.20% short of its 52-week high of $519.88, which the company achieved on November 8th.

Related Beal, the Boston office of Related Cos., has topped out construction of Leiden Center II at Innovation Square, a 345,000-square-foot life sciences project in Boston. The 1.8-acre site is ...

However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Invagen Pharmaceuticals Inc. will add 70 medical manufacturing jobs with a state tax incentive program worth almost $1.8 ...

Vertex Pharmaceuticals has been making quiet waves lately, popping up on investors’ radars like a biotech whack-a-mole. With ...

Life science leaders flocked to the BIO International Convention this week, where there was still a sense of optimism.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...